Rare Disease Audience Data: From Insight to Action

Patients, Caregivers, and HCPs

From insight to action: how teams can use rare disease audience data

Data for data’s sake can sometimes be more complicated than helpful.

Instead, teams need evidence that helps answer practical questions. The Rare Disease Studies from M3 MI were designed around these questions, supporting teams by providing insights like identifying where diagnosis breaks down, which audiences need support, what shapes treatment decisions, where information is trusted and how engagement should change across the journey.

One study explores the experiences of patients and caregivers; the other examines the HCP perspective. Used independently or together, they can support a range of commercial, communication and research cases.

For brand teams: strengthen strategy across the journey

How to use: Brand teams can use the studies to map the patient and caregiver journey, identify diagnostic barriers and understand the factors affecting treatment initiation, change and adherence.

Impact: Detailed profiles—including demographics, social determinants of health, care pathways, professional characteristics and prescribing behaviour—can support segmentation and more relevant engagement. Media usage, information needs and digital behaviours can also help teams focus resources on the channels and content most useful at each stage.

Key questions the studies answer for brand teams: Where are delays most likely to occur? What information is missing before treatment decisions? Which practical pressures affect continuity of care? How do patient priorities compare with HCP considerations?

For agency media teams: plan around real audience behaviour

How to use: Agency teams can use patient, caregiver and HCP profiles to identify high-value audiences and understand how they use streaming, social media, online video, podcasts, mobile, television and other channels.

Impact: The studies also examine trusted sources, preferred formats, advocacy organisations, online communities, AI tools and professional resources. This can help teams move beyond broad reach towards media and content plans grounded in how audiences seek information and support.

Key questions the studies answer for agency media teams: Which channels matter at different journey stages? Where do patients and HCPs turn for guidance? How should content and media plans respond to AI-enabled search?

For media publishers and platforms: build more relevant content

How to use: Publishers can explore unmet information needs, treatment challenges and emerging behaviours across patients, caregivers and HCPs. These insights can inform editorial planning, sponsored content, newsletters, communities, events and other audience initiatives.

Impact: They can also help publishers demonstrate a more detailed understanding of rare disease audiences to advertisers and sponsors.

Key questions the studies answer for media publishers: Which topics are underserved? What formats and sources do audiences value? Where could new content support diagnosis, treatment or daily management?

For consulting and research firms: deepen landscape and opportunity assessments

How to: Consulting and research teams can use the studies to connect diagnosis, treatment, decision-making, information needs and disease management. Condition-level responses are available within analysis tools, while therapeutic area clusters support more stable reporting across low-incidence populations.

Impact: This can strengthen patient landscape assessments, commercial planning, audience strategy and analysis of emerging trends such as AI, social media and online communities.

Key questions the studies answer for consulting and research firms: Which barriers repeat across conditions? Where are the clearest opportunities for intervention? How do individual experiences compare with broader therapeutic-area patterns?

For cross-functional teams: connect decisions that are often made separately

The greatest value can come from comparing perspectives. Patient-reported treatment barriers can be viewed alongside HCP prescribing constraints. Caregiver responsibilities can be considered alongside patient support planning. Audience information needs can be connected with media behaviour and trusted sources.

This creates a stronger shared evidence base for brand, insights, patient services, market access, communications and media teams.

Flexible access for different workflows means the data can make a difference across the entire team, moving from high-level questions to more detailed audience exploration with ease.

Start with the decision

The most effective use case begins with a clear decision, not a long list of variables. Define the audience, journey stage and action you need to inform, then connect the patient, caregiver and HCP evidence that can bring the answer into focus.

Find out more

Explore M3 MI’s 2026 Rare Disease Studies and speak to the team about the use cases most relevant to your strategy.

Information

For more information on detailed study results from M3 MI, including at the specialty level, contact us at
info@M3-MI.com.